ACST Stock – (NASDAQ: ACST) is providing an update on the usage

ACST Stock – (NASDAQ: ACST) is giving an update on the usage

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually providing an update on the usage of its “at the market” equity offering program.

As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to put into practice a “at the market” equity offering system under which Acasti may well issue as well as sell from time to time its everyday shares having an aggregate offering price of up to $75 million through the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions found on January 27, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares were offered at prevailing market rates averaging US$1.0747 per share. No securities were marketed throughout the facilities of the TSXV or maybe, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333-239538) as made effective on July 7, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and outstanding as of March 5, 2021.

The additional capital raised has strengthened Acasti’s balance sheet and can supply the Company with extra freedom in its ongoing review process to check out as well as evaluate strategic alternatives.

About Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescription medications making use of OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety as well as efficacy for lowering triglycerides in patients with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for individuals with serious HTG.

Forward Looking Statements – ACST Stock

Statements of that press release that aren’t statements of current or historical truth constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward looking statements include known and unknown risks, uncertainties, along with other unknown elements that might cause the actual results of Acasti to be materially different from historical results and even as a result of any later outcomes expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, people are urged to look at statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be forward-looking and uncertain. People are actually cautioned not to place undue reliance on these forward-looking statements, which speak simply as of the date of this press release. Forward-looking assertions in that press release include, but aren’t limited to, statements or info concerning Acasti’s strategy, future operations and its review of strategic options.

The forward-looking statements found in this specific press release are expressly qualified in the entirety of theirs by this alerting statement, the “Special Note Regarding Forward-Looking Statements” area found in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q, which are actually readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and on the investor aisle of Acasti’s website at www.acastipharma.com. Most forward-looking statements in that press release are produced as of the particular date of this press release.

ACST Stock – Acasti doesn’t undertake to redesign any such forward-looking statements whether as a consequence of info that is brand new , future events or otherwise, except as called for by law. The forward-looking statements contained herein are also subject typically to assumptions and risks and uncertainties that are described from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, like Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q under the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is giving an update on the usage

Comments are Disabled